Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NAGE stock hub

Niagen Bioscience, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NAGEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

332.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NAGE

In the news

Latest news · NAGE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E16.2

P25 12.3P50 18.4P75 33.1

Trailing P/E19.9

P25 14.9P50 23.2P75 38.5

ROE27.1

P25 -105.6P50 -46.5P75 -3.1

ROIC63.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NAGE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

243

Groups with data

Currency

USD

Showing 243 of 243 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000851773
Company name	Niagen Bioscience, Inc.
Country	United States
Country code	US
Cusip	171077407
Employees	117
Employees Change	13%
Employees Change Percent	12.5
Enterprise value	$269M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US1710774076
Last refreshed	2026-05-10
Market cap	$332.8M
Market cap category	Small-Cap
Price	$4.17
Price currency	USD
Rev Per Employee	1,114,666.67x
Sector	Healthcare
Symbol	NAGE
Website	https://www.niagenbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.6%
EV Earnings	14.43x
EV Sales Forward	1.73x
EV/EBIT	24.23x
EV/EBITDA	22.45x
EV/FCF	65.51x
EV/Sales	2.06x
FCF yield	1.23%
Forward P/E	16.24x
P/B ratio	4.02x
P/E ratio	19.86x
P/S ratio	2.55x
PS Forward	2.14x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	8.51%
EBITDA Margin	9.19%
FCF margin	3.15%
Gross margin	64.28%
Gross Profit	$83.8M
Gross Profit Growth	24.27%
Gross Profit Growth Q	3.34%
Gross Profit Growth3 Y	22.34%
Gross Profit Growth5 Y	18.29%
Net Income	$18.6M
Net Income Growth	32.13%
Net Income Growth Q	24.79%
Net Income Growth Quarters	1%
Net Income Growth Years	4%
Pretax Margin	15.1%
Profit Margin	14.29%
Profit Per Employee	$159,291
Profitable Years	2
ROA	7.09
Roa5y	-8.87
ROCE	12.13
ROE	27.07
Roe5y	-26.69
ROIC	63.23
Roic5y	-94.24

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-1.06%
Cagr15y	-0.89%
Cagr1y	-50.67%
Cagr3y	45.27%
Cagr5y	-11.15%
EPS Growth	17.35
EPS Growth Q	16.67
EPS Growth Quarters	1
EPS Growth Years	4
FCF Growth	-78.99%
OCF Growth	-77.52%
Revenue Growth	20.84x
Revenue Growth Q	3.26x
Revenue Growth Quarters	8x
Revenue Growth Years	8x
Revenue Growth3 Y	19.02x
Revenue Growth5 Y	16.96x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.33
Assets	$114.3M
Cash	$66.4M
Current Assets	$105.1M
Current Liabilities	$22.8M
Debt	$2.6M
Debt EBITDA	$0.19
Debt Equity	$0.03
Debt FCF	$0.63
Equity	$82.3M
Liabilities	$32M
Long Term Assets	$9.2M
Long Term Liabilities	$9.2M
Net Cash	$63.8M
Net Cash By Market Cap	$19.18
Net Cash Growth	22.87%
Net Debt EBITDA	$-5.33
Net Debt Equity	$-0.78
Net Debt FCF	$-15.54
Tangible Book Value	$76.8M
Tangible Book Value Per Share	$0.97
WACC	16.07

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.61
Inventory Turnover	2.65
Net Working Capital	$16.9M
Quick ratio	3.48
Working Capital	$82.3M
Working Capital Turnover	$1.89

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-7.04%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-10.13%
1Y total return	-50.65%
200-day SMA	6.83
3Y total return	206.62%
50-day SMA	4.72
50-day SMA vs 200-day SMA	50under200
5Y total return	-44.62%
All Time High	23.66
All Time High Change	-82.38%
All Time High Date	2021-02-25
All Time Low	0.33
All Time Low Change	1,163.64%
All Time Low Date	2009-08-03
ATR	0.26
Beta	2.17
Beta1y	1.7
Beta2y	0.94
Ch YTD	-34.43
High	4.26
High52	14.69
High52 Date	2025-06-30
High52ch	-71.61%
Low	4.04
Low52	4.04
Low52 Date	2026-05-07
Low52ch	3.27%
Ma50ch	-11.65%
Premarket Change Percent	0.72
Premarket Price	$4.22
Premarket Volume	7,029
Price vs 200-day SMA	-38.95%
RSI	36
RSI Monthly	43.68
RSI Weekly	30.91
Sharpe ratio	-1.09x
Sortino ratio	-1.31
Total Return	-7.04%
Tr YTD	-34.43
Tr15y	-12.58%
Tr1m	-6.71%
Tr1w	-14.02%
Tr3m	-19.81%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$0.06
Earnings EPS Estimate Growth	0
Earnings Revenue Estimate	30,728,000x
Earnings Revenue Estimate Growth	0.81x
Operating Income	$11.1M
Operating Income Growth	-16.09
Operating Income Growth Q	-66.97
Operating margin	8.51
Price target	$15
Price Target Change	$260

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	52,246,688%
Float Percent	65.46%
Net Borrowing	-9,000
Shares Insiders	29.53%
Shares Institutions	45.42%
Shares Out	79,811,327
Shares Qo Q	0.14%
Shares Yo Y	7.04%
Short Float	10.44%
Short Ratio	5.72
Short Shares	6.83

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-2.6M
Average Volume	826,132.25x
Bv Per Share	1.03
CAPEX	$-321,000
Ch10y	-10.13
Ch15y	-12.58
Ch1m	-6.71
Ch1w	-14.02
Ch1y	-50.65
Ch3m	-19.81
Ch3y	206.6
Ch5y	-44.62
Ch6m	-39.04
Change	-0.48%
Change From Open	-1.42
Close	4.19
Days Gap	0.95
Depreciation Amortization	881,000
Dollar Volume	7,453,749.9
Earnings Date	2026-05-06
Earnings Time	amc
EBIT	$11.1M
EBITDA	$12M
EPS	$0.21
F Score	5
FCF	$4.1M
FCF EV Yield	1.53x
FCF Per Share	$0.05
Financing CF	1,521,000
Fiscal Year End	December
Founded	1,999
Graham Number	2.21041
Graham Upside	-46.99
Income Tax	$1.1M
Investing CF	4,985,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2016-04-13
Last Split Type	Reverse
Ma150	5.91
Ma150ch	-29.39%
Ma20	4.76
Ma20ch	-12.32%
Net CF	10,933,000
Next Earnings Date	2026-08-05
Open	4.23
Optionable	Yes
P FCF Ratio	81.06
P OCF Ratio	75.18
Position In Range	59.63
Post Close	4.17
Postmarket Change Percent	0.72
Postmarket Price	$4.2
Ppne	3,317,000
Pre Close	4.19
Price Date	2026-05-08
Price EBITDA	$27.78
Ptbv Ratio	4.33
Relative Volume	2.16x
Revenue	130,416,000x
SBC By Revenue	5.14x
Share Based Comp	6,708,000
Tax By Revenue	0.81x
Tax Rate	5.38%
Tr6m	-39.04%
Us State	California
Volume	1,787,470
Z Score	12.45

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NAGE pay a dividend?

Capital-return profile for this ticker.

Performance

NAGE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NAGE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+45.4%

Float: +65.5% of shares outstanding

Insider ownership

+29.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NAGE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

36.0

Neutral momentum band

Price vs 200-day MA

-39.0%

50/200-day relationship not available

Beta (5Y)

2.17

More volatile than the market

Sharpe ratio

-1.09

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NAGE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NAGE stock rating?

Niagen Bioscience, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NAGE analysis?

The full report lives at /stocks/NAGE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NAGE?

The latest report frames NAGE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NAGE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.